NIP
BMRN icon

Nicholas Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nicholas Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-119,372
Closed -$12.4M – 191
2022
Q4 		$12.4M Buy
+119,372
New +$11.2M 1.08% 37
2021
Q1 		– Sell
-81,530
Closed -$7.15M – 190
2020
Q4 		$7.15M Sell
81,530
-14,746
-15% -$1.17M 0.55% 62
2020
Q3 		$7.33M Buy
+96,276
New +$9.74M 0.79% 47
2020
Q2 		– Sell
-26,302
Closed -$2.22M – 176
2020
Q1 		$2.22M Buy
+26,302
New +$2.27M 0.43% 91
2018
Q2 		– Sell
-17,548
Closed -$1.42M – 227
2018
Q1 		$1.42M Sell
17,548
-20,494
-54% -$1.76M 0.1% 210
2017
Q4 		$3.39M Buy
38,042
+213
+0.6% +$18.5K 0.22% 149
2017
Q3 		$3.52M Sell
37,829
-722
-2% -$63.8K 0.24% 137
2017
Q2 		$3.5M Buy
38,551
+4,176
+12% +$380K 0.25% 143
2017
Q1 		$3.02M Sell
34,375
-3,541
-9% -$315K 0.21% 174
2016
Q4 		$3.14M Sell
37,916
-21,745
-36% -$1.87M 0.24% 177
2016
Q3 		$5.52M Buy
59,661
+1,922
+3% +$181K 0.37% 77
2016
Q2 		$4.49M Buy
57,739
+21,467
+59% +$1.82M 0.31% 116
2016
Q1 		$2.99M Buy
36,272
+11,207
+45% +$912K 0.22% 190
2015
Q4 		$2.63M Sell
25,065
-19,521
-44% -$2.04M 0.18% 217
2015
Q3 		$4.7M Buy
44,586
+1,941
+5% +$259K 0.34% 112
2015
Q2 		$5.83M Buy
42,645
+635
+2% +$78.7K 0.37% 77
2015
Q1 		$5.24M Buy
+42,010
New +$4.45M 0.33% 100
2014
Q2 		– Sell
-25,639
Closed -$1.75M – 274
2014
Q1 		$1.75M Sell
25,639
-9,297
-27% -$685K 0.14% 236
2013
Q4 		$2.46M Sell
34,936
-23
-0.1% -$1.56K 0.19% 164
2013
Q3 		$2.52M Sell
34,959
-5,160
-13% -$343K 0.21% 154
2013
Q2 		$2.24M Buy
+40,119
New +$2.5M 0.21% 158

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nicholas Investment Partners's BMRN Position: Q1 2023 in Review

Nicholas Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 119,372 shares — an estimated $12.4M sold.

Nicholas Investment Partners first reported a position in BMRN in Q2 2013 and held it in 21 quarters. The position peaked at $12.4M in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Nicholas Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Nicholas Investment Partners sold 119,372 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $12.4M.
  • Nicholas Investment Partners first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Nicholas Investment Partners's BioMarin Pharmaceuticals position peaked at $12.4M in Q4 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Nicholas Investment Partners's 13F filing for Q1 2023, filed 12 May 2023.